In November 2011 MBBP client Alnylam Pharmaceuticals, Inc. entered into a partnership with pharmaceutical giant GlaxoSmithKline plc. (GSK) relating to use of its RNA interference technology to enhance GSK’s vaccine products. On July 30th the partnership paid off, as Alnylam received a $3.2 million milestone payment from GSK with a possibility of future payments on unit product sales if its VaxiRNA technology is successfully applied in the manufacturing of a commercial vaccine.
Congratulations Alnylam Pharmaceuticals!
To learn more, please see the full article in the Boston Business Journal.